Now ICMR bids this big thing regarding corona vaccine launch

The Indian Medical Research Center (ICMR), while giving its clarification to the heads of 12 hospitals of the country by launching the Corona virus COVID-19 vaccine vaccine by 15 August, has said that it had written it to save the entire process from red tape.

The ICMR said on Sunday that all medical hospitals have a committee of ethics to approve such tests. These committees meet at a pre-determined time. In such a situation, a letter was written to the heads of all clinical trial sites, keeping in mind that there is no undue delay in obtaining approval for human trials of the COVID-19 vaccine.

On July 2, ICMR wrote a letter to the heads of the 12 clinical sites selected for the vaccine trial, stating that the clinical trial of the COVID-19 vaccine being made in collaboration with Bharat Biotech International Ltd. Used to be. After completing all clinical trials, the vaccine is set to be launched by 15 August.

Bharat Biotech is working steadily to achieve this goal, but its end result depends on the cooperation of all clinical trial sites involved in the project. In view of the Kovid-19 epidemic and the need to launch its vaccine, all of you are advised that all the necessary approvals to start the clinical trial of launching the vaccine should be obtained soon and to ensure that its trials Registration of volunteering for volunteering should start by July 7. High priority should be given to this project and the works should be completed at the specified time.

The ICMR letter expressed serious concern to health experts and researchers and said that the quality of the vaccine should not be compromised in such a hurry to launch it. Working in such deadline will launch the vaccine with incomplete data.

ICMR has stated its stand that for it the safety and interest of the people of the country is paramount. Only after closely examining the data of the pre-clinical study did the Indian Drug Controller General approve the clinical trials of phase one and phase two.

Fast-tracking clinical trials of the COVID-19 vaccine by ICMR is in accordance with global standards. The pre-clinical trial has ended successfully. Its human trials are to begin now. This process did not impede red tape, which is why the Director General of ICMR wrote a letter to investigators at the clinical trial site.

It is noteworthy that ICMR has selected hospitals in Andhra Pradesh, Haryana, New Delhi, Bihar, Karnataka, Maharashtra, Uttar Pradesh, Tamil Nadu, Telangana, Odisha and Goa as clinical trials. Candidates will be selected for human trials of both stages of the COVID-19 vaccine in these hospitals.